Corbus Pharmaceuticals Holdings Inc. closed $42.39 short of its 52-week high ($61.90), which the company reached on July 31st ...

Corbus Pharmaceuticals and Novo Nordisk stocks plunge following cannabinoid receptor drug trials, raising concerns over ...

Novo Nordisk announced positive Phase 2a trial results for monlunabant, showing significant weight loss with a 10 mg dose.

Novo Nordisk stock tumbled Friday — pulling Corbus into a steep dive — after its new obesity drug caused neuropsychiatric side effects.

Ginkgo Bioworks is pivoting: Once a synthetic biology darling, the flailing company has now turned to AI-driven protein ...

The US stock markets opened lower on Friday, September 20, as investors held back after a jump in the previous session, which ...

Novo Nordisk's shares fell nearly 5% on Friday after results from a Phase 2a trial of the Danish drugmaker's experimental ...

The best performers of the session on the Dow Jones Industrial Average were Nike Inc (NYSE: NKE ), which rose 6.84% or 5.54 ...

Novo Nodrisk’s cannabinoid receptor–targeting obesity pill was picked up in the $1.1 billion acquisition of Inversago ...

Novo Nordisk stock tumbled Friday — pulling Corbus into a steep dive — after its new obesity drug caused neuropsychiatric side effects. Stock Market Today: The Dow Jones fell Friday as Nike surged on ...